[FURL=https://www.industryarc.com/Report/19553/myasthenia-gravis-treatment-market.html?utm_source=BriefingWire&utm_medium=PressRelease&utm_campaign=PaidPressRelease] Myasthenia Gravis Treatment Market[/FURL] size was valued at $1.6 billion by 2020 and is anticipated to reach $2.2 billion by 2026 growing at a CAGR of 7.8% during the forecast period 2021-2026. The Myasthenia Gravis Treatment market growth rate is attributed to the rising focus on research and developmental activities. Thus, the several drugs are in pipeline under clinical development phases which are poised to get approved in the forecast years offering targeted treatment options in the management of myasthenia gravis and are anticipated to create new opportunities. Myasthenia gravis (MG) is a type of chronic neuromuscular autoimmune disease that causes arm and leg weakness in the skeletal muscles. Symptoms of myasthenia gravis are double vision, facial paralysis, trouble walking, dropping eyelids. Tests such as the repeated nerve stimulation test, blood test for antibodies, edrophonium test, computed tomography (CT) and magnetic resonance imaging tests are used to diagnose this disease (MRI). Drugs containing corticosteroids (azathioprine and cyclosporine) and inhibitors of acetylcholine esterase (Edrophonium and Pyridostigmine) are used to treat MG. In the U.S., about 14-40 per 100,000 individuals suffer from myasthenia gravis, according to the National Association for Rare Disorders (NORD). Key Takeaways
North America dominated the Myasthenia Gravis Treatment market with a share of 37.2% in the year 2020.
The factors such as rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases are amongst the major factor projected to impel growth of Myasthenia Gravis Treatment Market.
Rapidly rising population with myasthenia gravis in emerging countries and serving the untapped geriatric population with autoimmune disease creates lucrative opportunities paving a way for the growth in the market during forecast period 2021-2026.
Request for Sample of the Report @ [FURL]https://www.industryarc.com/pdfdownload.php?id=19553[/FURL]
Myasthenia Gravis Treatment Market Drivers
Consistent Activities for Research and Development
The Myasthenia Gravis Treatment market is poised to receive upswing owing to consistent research and development activities that are anticipated to propel growth of the myasthenia gravis treatment market.
Myasthenia Gravis Treatment Market top 10 companies are Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., Shire plc. Alexion Pharmaceuticals, Astellas Pharma
About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services.